Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):202–209. doi: 10.1097/QAI.0000000000002236

Figure 2.

Figure 2.

The proportion of women retained in care (with 95% confidence intervals) at the MCH-ART primary trial outcome (approximately 12 months postpartum) and the two 12-month windows of time thereafter (n=450, all women enrolled in MCH-ART who had not withdrawn and were not known to have died).